Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus

Journal of Virology

Volumn 86, Issue 23, 2012, Pages 12676-12685

  Noah Sather, D ^a   Carbonetti, Sara ^a   Kehayia, Jenny ^a,b   Kraft, Zane ^a   Mikell, Iliyana ^a,c   Scheid, Johannes F ^d   Klein, Florian ^d   Stamatatosa, Leonidas ^a,c  

^a Seattle BioMed   (United States)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c UNIVERSITY OF WASHINGTON   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE GLYCOPROTEIN; VIRUS ENVELOPE PROTEIN;

ANTIBODY COMBINING SITE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CELL SURFACE; CLADISTICS; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; MOLECULAR DYNAMICS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS IDENTIFICATION; VIRUS IMMUNITY; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; ANTIGENS, CD4; BINDING SITES, ANTIBODY; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTAGENESIS; MUTATION; NEUTRALIZATION TESTS; VIRUS INTERNALIZATION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84869204900     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01893-12     Document Type: Article

References (47)

1. Abdelwahab SF, et al. 2003. HIV-1-suppressive factors are secreted by CD4+ T cells during primary immune responses. Proc. Natl. Acad. Sci. U. S. A. 100, 15006-15010.
2. Abela IA, et al. 2012. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog. 8, e1002634. doi, 10.1371/journal.ppat.1002634.
3. Bar KJ, et al. 2012. Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog. 8, e1002721. doi, 10.1371/journal.ppat.1002721.
4. Binley JM, et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82, 11651-11668.
5. Bonsignori M, et al. 2011. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85, 9998-10009.
6. Dhillon AK, et al. 2007. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 81, 6548-6562.
7. Diskin R, et al. 2011. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334, 1289-1293.
8. Doria-Rose NA, et al. 2010. Breadth of HIV-specific neutralizing activity in sera, clustering analysis and association with clinical variables. J. Virol. 84, 1631-1636.
9. Dorrucci M, et al. 2007. Temporal trends in postseroconversion CD4 cell count and HIV load, the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. J. Infect. Dis. 195, 525-534.
10. Duenas-Decamp MJ, Peters P, Burton D, Clapham PR. 2008. Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop. J. Virol. 82, 5807-5814.
11. Frost SD, et al. 2005. Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J. Virol. 79, 6523-6527.
12. Gras L, et al. 2009. Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands. PLoS One 4, e7365. doi, 10.1371/journal.pone.0007365.
13. Gray ES, et al. 2009. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J. Virol. 83, 8925-8937.
14. Herbeck JT, et al. 2008. Lack of evidence for changing virulence of HIV-1 in North America. PLoS One 3, e1525. doi, 10.1371/journal.pone.0001525.
15. Klein F, et al. 2012. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J. Exp. Med. 209, 1469-1479.
16. Kwong PD, et al. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659.
17. Lavine CL, et al. 2012. High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during infection of human immunodeficiency virus type 1. J. Virol. 86, 2153-2164.
18. Li M, et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108-10125.
19. Li Y, et al. 2007. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13, 1032-1034.
20. Li Y, et al. 2011. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J. Virol. 85, 8954-8967.
21. Li Y, et al. 2009. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J. Virol. 83, 1045-1059.
22. McLellan JS, et al. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336-343.
23. Mikell I, et al. 2011. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7, e1001251. doi, 10.1371/ journal.ppat.1001251.
24. Moore PL, et al. 2009. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 5, e1000598. doi, 10.1371/journal.ppat.1000598.
25. Moulard M, et al. 2002. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl. Acad. Sci. U. S. A. 99, 6913-6918.
26. Neumann T, et al. 2005. T20-insensitive HIV-1 from naive patients exhibits high viral fitness in a novel dual-color competition assay on primary cells. Virology 333, 251-262.
27. Pejchal R, et al. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334, 1097-1103.
28. Pietzsch J, et al. 2010. Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. J. Exp. Med. 207, 1995-2002.
29. Richman DD, Wrin T, Little SJ, Petropoulos CJ. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 100, 4144-4149.
30. Rong R, et al. 2009. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 5, e1000594. doi, 10.1371/journal.ppat.1000594.
31. Sajadi MM, et al. 2011. Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. J. Acquir. Immune Defic. Syndr. 57, 9-15.
32. Sather DN, et al. 2009. Factors associated with the development of crossreactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83, 757-769.
33. Scanlan CN, et al. 2002. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1¡2 mannose residues on the outer face of gp120. J. Virol. 76, 7306-7321.
34. Scheid JF, et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636-640.
35. Scheid JF, et al. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637.
36. Thali M, et al. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67, 3978-3988.
37. Troude P, et al. 2009. No evidence of a change in HIV-1 virulence since 1996 in France. AIDS 23, 1261-1267.
38. van Gils MJ, et al. 2010. Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors. J. Virol. 84, 3576-3585.
39. Walker LM, et al. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470.
40. Walker LM, et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289.
41. Wei X, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422, 307-312.
42. West AP, Jr, Diskin R, Nussenzweig MC, Bjorkman PJ. 2012. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. U. S. A. 109, E2083-E2090.
43. Wu X, et al. 2012. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J. Virol. 86, 5844-5856.
44. Wu X, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861.
45. Wu X, et al. 2009. Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J. Virol. 83, 10892-10907.
46. Wu X, et al. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333, 1593-1602.
47. Zhou T, et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817.